Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer.

Autor: Anttinen M; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Mäkelä P; Department of Diagnostic Radiology, University of Turku and Turku University Hospital, Turku, Finland., Nurminen P; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Yli-Pietilä E; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Suomi V; Department of Medical Physics and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland., Sainio T; Department of Medical Physics and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland., Saunavaara J; Department of Medical Physics and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland., Taimen P; Institute of Biomedicine and Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland., Blanco Sequeiros R; Department of Diagnostic Radiology, University of Turku and Turku University Hospital, Turku, Finland., Boström PJ; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland.
Jazyk: angličtina
Zdroj: Scandinavian journal of urology [Scand J Urol] 2020 Dec; Vol. 54 (6), pp. 481-486. Date of Electronic Publication: 2020 Sep 08.
DOI: 10.1080/21681805.2020.1814857
Abstrakt: Purpose: Locally advanced prostate cancer can cause bladder outlet obstruction, gross hematuria and frequent hospitalization. While these complications are commonly treated by palliative transurethral resection of the prostate, the improvement is often insufficient. The purpose of this study was to evaluate the safety and feasibility of MRI-guided transurethral ultrasound ablation as an alternative palliative treatment option (pTULSA) for men suffering from symptomatic locally advanced prostate cancer.
Methods: This prospective, phase one study included 10 men in need of palliative surgical intervention due to urinary retention and gross hematuria caused by locally advanced prostate cancer. Patients were followed for 1 year at 3-month intervals. Time without catheter, time without hematuria, reduction in hospitalization time, and adverse events were measured.
Results: Ten patients with locally advanced prostate cancer were enrolled, all having continuous catheterization due to urinary retention and nine had gross hematuria before treatment. At 1 week post-pTULSA five patients were catheter-free. At last follow-up catheter-free and gross hematuria-free rates were 70% and 100%, respectively. Average hospitalization time from local complications reduced from 7.3 to 1.4 days in the 6 months before and after pTULSA. No > Grade 2 treatment related adverse events were reported, with all five being urinary tract infections.
Conclusions: pTULSA appears safe and feasible for palliative ablation of locally advanced prostate cancer. The therapy seems to accomplish long-term hematuria control, can relieve bladder outlet obstruction in selected patients, and seems to reduce the burden of hospitalization due to local complications. Trial Registration Number: NCT03350529.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje